You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Interleukin-6: a new therapeutic target
|
|---|---|
| Published in |
Arthritis Research & Therapy, July 2006
|
| DOI | 10.1186/ar1969 |
| Pubmed ID | |
| Authors |
Josef S Smolen, Ravinder N Maini |
| Abstract |
The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the treatment arena. One of these is rituximab, which depletes B cells, and another, abatacept, interferes with T-cell co-stimulation. However, although these agents may be effective in a number of patients who fail to respond to TNF blockade, they only rarely induce remission and overall 50% response rates do not exceed those with the TNF inhibitors. Among the major proinflammatory cytokines, IL-6 plays a pleiotropic role both in terms of activating the inflammatory response and osteoclastogenesis. Here, we review recent phase II trials of tocilizumab, a humanized anti-IL-6 receptor antibody that achieves a significant therapeutic response rate. |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 5% |
| Denmark | 2 | 3% |
| Germany | 2 | 3% |
| Australia | 1 | 2% |
| Unknown | 54 | 87% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 24% |
| Student > Ph. D. Student | 13 | 21% |
| Student > Bachelor | 9 | 15% |
| Other | 7 | 11% |
| Student > Master | 5 | 8% |
| Other | 8 | 13% |
| Unknown | 5 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 19 | 31% |
| Medicine and Dentistry | 14 | 23% |
| Biochemistry, Genetics and Molecular Biology | 7 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Chemistry | 4 | 6% |
| Other | 8 | 13% |
| Unknown | 5 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2020.
All research outputs
#4,300,658
of 25,373,627 outputs
Outputs from Arthritis Research & Therapy
#958
of 3,381 outputs
Outputs of similar age
#12,894
of 90,161 outputs
Outputs of similar age from Arthritis Research & Therapy
#6
of 24 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 90,161 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.